Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: A randomized, noncomparative phase II study

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2205-2210

  Borg, Christophe ^a   Andre T ^b   Mantion, G ^a   Boudghene F ^c   Mornex, F ^d   Maingon, P ^e   Adenis, A ^f   Azria, D ^g   Piutti, M ^h   Morsli, O ^h   Bosset, J F ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL TENON   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e Biostatistic and Quality of Life Unit Georges François Leclerc Center   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g CENTRE VAL D AURELLE   (France)

^h Roche Laboratories   (France)

Author keywords

5 FU; Bevacizumab; Chemoradiotherapy; Neoadjuvant; Oxaliplatin; Rectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HERNIA; HUMAN; HYPERTENSION; ILEITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM FISTULA; RECTUM SURGERY; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREATMENT OUTCOME; URINE RETENTION; WOUND HEALING IMPAIRMENT; ABDOMINAL SURGERY; ADJUVANT THERAPY; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RECTAL NEOPLASMS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 84934297863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu377     Document Type: Article

References (29)

1. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304.
2. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
3. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
4. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
5. Petersen SH, Harling H, Kirkeby LT et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3: CD004078.
6. Khrizman P, Niland JC, ter Veer A et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013; 31: 30-38.
7. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
8. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
9. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
10. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
11. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
12. Kennecke H, Berry S, Wong R et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer 2012; 48: 37-45.
13. Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg 2009; 208: 269-278.
14. Willett CG, Duda DG, Ancukiewicz M et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 845-851.
15. Crane CH, Eng C, Feig B et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830.
16. Velenik V, Ocvirk J, Music M et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011; 6: 105.
17. Nogue M, Salud A, Vicente P et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011; 16: 614-620.
18. Gasparini G, Torino F, Ueno T et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141-150.
19. Dipetrillo T, Pricolo V, Lagares-Garcia J et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 124-129.
20. Landry JC, Feng Y, Cohen SJ et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer 2013; 119: 1521-1527.
21. Dellas K, Höhler T, Reese T et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013; 8: 90.
22. Gerard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644.
23. Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780.
24. Rodel C, Liersch T, Becker H et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687.
25. Roh MS, Yothers GA. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29(suppl); abstr 3503.
26. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
27. Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRIdefined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-248.
28. Fernandez-Martos C, Pericay C, Aparicio J et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865.
29. Maréchal R, Vos B, Polus M et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012; 23: 1525-1530.